Drug discovery by pharmaceutical companies use the primary culture of human hepatocytes in preclinical toxicology studies of candidate compounds and evaluations of metabolites. However, as the drug metabolizing function of the culture steeply decreases in a couple of days, development of a liver structure with a longer lasting function is awaited in the development fields.
Cyfuse has successfully developed a liver structure exerting high liver functions lasting a long time from several types of cells constituting the liver with its unique three-dimensional cell layering technology without using a scaffold.
This study result was highly appreciated by academic societies, for example, selected as the Lecture Highlight in the 136th Annual Meeting of the Pharmaceutical Society of Japan in March 2016. Furthermore, in April 2017, our article on the research and development of a liver structure with a function to detect human-specific toxicity (tissue for research) was adopted by BBREP (Biochemistry and Biophysics Reports).
If a liver structure with such functions is used in fields of preclinical metabolism and safety studies of candidate drugs, risks in development will be reduced after the beginning of the clinical phase, by early detection of human-specific toxicity previously undetectable by animal studies, and advance prediction of possible adverse events in human livers before clinical studies.
As described above, Cyfuse's original base technology is expected not only to be put into practical use in the field of regenerative medicine but also to contribute multilaterally to drug evaluations of new drug developments, elucidation of disease mechanisms, cost reductions, and improvements in research efficiency in the field of drug discovery support.